Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Phase 3RecruitingNCT06643130

JW Pharmaceutical162 enrolled

Overview

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

162

Conditions

Hypertension Dyslipidemia

Interventions

JW0104+C2402DRUG

For 8 weeks(PO (Per Oral), QD)

JW0104+C2403DRUG

For 8 weeks(PO, QD)

C2402DRUG

For 8 weeks(PO, QD)

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with hypertension and dyslipidemia Exclusion Criteria: * The subject not meet the specified msBP and LDL-C level

Locations (1)

Gangdong Sacred Heart Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Change from baseline in msSBP (Systolic Blood Pressure)

Check msSBP

Time frame: week 8

Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol)

Check LDL-C

Time frame: week 8

Secondary Outcomes

change from baseline in msSBP

Check msSBP

Time frame: week 4

Change and percent change from baseline in LDL-C

Check LDL-C

Time frame: week 4

Central Contacts

Minjung Kim

CONTACT

+82-2-840-6861 kmj@jwhealthcare.com

Dongryung Lee

CONTACT

+82-2-840-6982 dongryung.lee@jwhealthcare.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.